N-acetylcysteine in patients with COPD exacerbations associated with increased sputum

Basit Öğe Kaydı
dc.authoridAytemur, Zeynep Ayfer/0000-0003-0421-907X
dc.authoridKOSE, Timur/0000-0002-5238-9738
dc.authoridOzdemir, Ozer/0000-0002-8884-0682
dc.authorid/0000-0001-6209-7758
dc.authorwosidAytemur, Zeynep Ayfer/ABI-7452-2020
dc.authorwosidKOSE, Timur/ABH-3197-2021
dc.authorwosidOzdemir, Ozer/GQZ-6473-2022
dc.authorwosidSayiner, Abdullah/A-7283-2018
dc.contributor.authorAytemur, Zeynep Ayfer
dc.contributor.authorBaysak, Aysegul
dc.contributor.authorOzdemir, Ozer
dc.contributor.authorKose, Timur
dc.contributor.authorSayiner, Abdullah
dc.date.accessioned2024-08-04T20:41:08Z
dc.date.available2024-08-04T20:41:08Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground N-acetylcysteine (NAC) has been shown not to alter the clinical outcome in chronic obstructive pulmonary disease (COPD) exacerbations. However, NAC may improve symptoms through its mucolytic effect in the subgroup of patients with increased sputum production. The aims of this study were to determine whether NAC improves symptoms and pulmonary function in patients with COPD exacerbation and increased sputum production. Methods This was a placebo-controlled study, where patients with severe COPD and increased sputum production, who were hospitalized for an exacerbation, were included. They were randomized to receive either NAC 200 mg tid or placebo in addition to the usual treatment. Results Forty-two patients were included and were equally distributed to NAC and placebo groups. The symptoms, namely, ease of sputum production and dyspnea at rest and on exertion significantly improved in both groups; but there was no difference in improvement between NAC and placebo groups (p = 0.96, 0.62, 0.31, respectively). Similarly, forced expiratory volume-one second (FEV1) and PaO2 levels improved significantly in NAC (964 +/- 599-1239 +/- 543 ml, p < 0.001, and 57.5 +/- 14.5-70.5 +/- 16.0 mmHg, p < 0.001, respectively) and placebo groups (981 +/- 514-1180 +/- 535 ml, p < 0.001 and 57.9 +/- 14.3-68.7 +/- 19.0 mmHg, p < 0.001, respectively), without any difference between the two groups (p = 0.52 and 0.57). There was no difference in the number of exacerbations during the 6-month follow-up period. Conclusion NAC does not have any beneficial effect on clinical outcomes in patients with severe COPD exacerbation associated with increased and/or viscous mucus production.en_US
dc.identifier.doi10.1007/s00508-014-0692-4
dc.identifier.endpage261en_US
dc.identifier.issn0043-5325
dc.identifier.issn1613-7671
dc.identifier.issue7-8en_US
dc.identifier.pmid25595117en_US
dc.identifier.scopus2-s2.0-84939996061en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage256en_US
dc.identifier.urihttps://doi.org/10.1007/s00508-014-0692-4
dc.identifier.urihttps://hdl.handle.net/11616/96947
dc.identifier.volume127en_US
dc.identifier.wosWOS:000354549100004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofWiener Klinische Wochenschriften_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic obstructive pulmonary diseaseen_US
dc.subjectExacerbationen_US
dc.subjectTreatmenten_US
dc.subjectN-Acetylcysteineen_US
dc.subjectMucolyticen_US
dc.titleN-acetylcysteine in patients with COPD exacerbations associated with increased sputumen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu